Telephone Support Intervention Beneficial for BRCA Carriers

This article originally appeared here.
Telephone Support Intervention Beneficial for <i>BRCA</i> Carriers
Telephone Support Intervention Beneficial for BRCA Carriers

(HealthDay News) -- A telephone-based, peer-support program can reduce distress and unmet information needs among women with a BRCA1 or BRCA2 mutation, according to a study published online Nov. 17 in the Journal of Clinical Oncology.

Victoria M. White, Ph.D., from the University of Melbourne in Australia, and colleagues examined the effectiveness of an intervention involving volunteers who contacted BRCA1/2-positive women multiple times over a four-month period to provide informational, emotional, and practical support. Participants who completed a baseline questionnaire and reported interest in talking to other mutation carriers were assigned to the usual-care group (UCG; 102 participants) or the intervention group (IG; 105 participants).

The researchers observed a greater decrease in breast cancer distress scores in the IG than the UCG at the end of the intervention (mean difference, −5.96; P = 0.002) and two months later (mean difference, −3.94; P = 0.04). Unmet information needs decreased more in the IG versus the UCG (P < 0.01), with unmet needs lower in the IG after the intervention. In the IG versus the UCG there was a greater decrease in Cognitive Appraisals About Genetic Testing stress subscale scores (P = 0.02), with significantly lower scores in the IG versus the UCG after the intervention (P < 0.01).

"The intervention is effective in reducing distress and unmet information needs for this group of women," the authors write.

Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs